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A Immunotherapy Leads to Clearance
of Early, but Not Late, Hyperphosphorylated
Tau Aggregates via the Proteasome
sion of other key components of AD neuropathology
such as those that involve the tau protein. Unfortunately,
the human clinical trial was halted due to the unforeseen
development of encephalitis in a small proportion of
patients (Check, 2002). Nevertheless, one brain sample
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were unaffected (Nicoll et al., 2003)—although clearly it
is difficult to draw firm conclusions from a single case
report. Thus, it remains unresolved whether preventingSummary
or clearing A accumulation will also affect other as-
pects of AD pathology such as neurofibrillary tangles.Amyloid- (A) plaques and neurofibrillary tangles are
the hallmark neuropathological lesions of Alzheimer’s Because tau can cause neurodegeneration in the ab-
sence of A (e.g., frontotemporal dementia with parkin-disease (AD). Using a triple transgenic model (3xTg-
AD) that develops both lesions in AD-relevant brain sonism-17) (Hutton et al., 1998), it is critically important
from a clinical perspective to determine whether the tauregions, we determined the consequence of A clear-
ance on the development of tau pathology. Here we pathology in the AD brain will also be impacted by anti-
A interventions.show that A immunotherapy reduces not only extra-
cellular Aplaques but also intracellular A accumula- The occurrence of both plaques and tangles in our
3xTg-AD mice allows us to directly assess whether thetion and most notably leads to the clearance of early
tau pathology. We find that A deposits are cleared onset and development of the tau pathology is modu-
lated following therapies designed to clear A (Oddo etfirst and subsequently reemerge prior to the tau pa-
thology, indicative of a hierarchical and direct relation- al., 2003b). Toward this end, we administered anti-A
antibodies into the hippocampus of the 3xTg-AD mice;ship between A and tau. The clearance of the tau
pathology is mediated by the proteasome and is de- this approach was shown by Morgan and colleagues
to effectively and rapidly reduce A deposits, with apendent on the phosphorylation state of tau, as hyper-
phosphorylated tau aggregates are unaffected by the discernible reduction in the A load by 24 hr (Wilcock
et al., 2003, 2004). Here we show a reduction not only ofA antibody treatment. These findings indicate that A
immunization may be useful for clearing both hallmark extracellular A deposits, including thioflavin-S-positive
structures, but also that the intracellular A load is rap-lesions of AD, provided that intervention occurs early
in the disease course. idly and markedly diminished. Notably, we find that intra-
hippocampal A immunization also reduces early tau
pathology. Whereas A deposits are cleared within 3Introduction
days, the tau lesions require a slightly longer time and
are not reduced until 5 days postinjection. Thus, A isAlzheimer’s disease is a progressive neurodegenerative
disorder that is the leading cause of dementia among cleared first, followed by the clearance of tau localized
in the somatodendritic compartment. Conversely, by 30the elderly. The two hallmark neuropathological lesions
of this disorder include the aberrant accumulation of days postinjection, A deposits have reemerged, al-
though the tau pathology is not apparent at this timethe amyloid -peptide (A) and intracellular inclusions
consisting of hyperphosphorylated tau protein. Because point.
Using an alternative approach, we show that ad-A, either as extracellular aggregates or perhaps an
intracellular form, appears to be an early and critical ministration of the -secretase inhibitor, N-[N-(3,5-diflu-
orophenacetyl)-L-alanyl]-S-phenylglycine t-butyl esterevent in the pathogenesis of AD, many therapeutic-
based strategies are aimed at reducing its formation or (DAPT), leads to similar results. Therefore, the finding
facilitating its clearance. that A-based interventions successfully clear the tau
Several immune-based strategies, including both ac- pathology in these 3xTg-AD mice provides compelling
tive and passive approaches with anti-A antibodies, evidence in support of the amyloid cascade hypothesis.
have been shown to dramatically prevent or reduce A The mechanism underlying the effect on tau is depen-
accumulation in the brains of APP transgenic mice (Bard dent on the activity of the proteasome, as blocking its
et al., 2000; Schenk et al., 1999; Sigurdsson et al., 2001). function prevents the immunotherapy-mediated clear-
These approaches protect transgenic mice from cogni- ance of tau. In addition, we find that the clearance of
tive decline (Dodart et al., 2002; Janus et al., 2000; Mor- tau is critically dependent on its phosphorylation state,
gan et al., 2000), and likewise also appear to slow cogni- as late-stage, hyperphosphorylated tau aggregates
tive decline in human AD patients (Hock et al., 2003). It appear unaffected by the A antibody treatment. Our
is presently unclear, however, whether lowering the A results indicate that A-targeted therapies may be use-
burden in the brain will also effectively halt the progres- ful for clearing both hallmark lesions of AD, provided
that the intervention is administered early in the dis-
ease course.*Correspondence: laferla@uci.edu
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Table 1. Age, Number, and Genotype of Mice Receiving Immunotherapy
Time Sacrificed Post
Age Number of Antibody Administration
Mice (Months) Mice Used Antibody Injected (in Days)
h3xTg-AD 12 3 Isotype control 7
h3xTg-AD 12 3 PBS 7
h3xTg-AD 12 3 HT7 7
h3xTg-AD 12 3 4G8 7
h3xTg-AD 12 11 1560 5–7
h3xTg-AD 12 3 1560 3
h3xTg-AD 12 6 1560 30
h3xTg-AD 12 3 1560 45
h3xTg-AD 12 5 1560  Epoxomicin 7
H3xTg-AD 6 3 PBS 7
H3xTg-AD 6 3 1560 7
H3xTg-AD 12 5 1560 7
Hemizygous and homozygous 3xTg-AD mice are indicated as h3xTg-AD and H3xTg-AD, respectively.
Results A Clearance Reverses Tau Aggregates
Because the 3xTg-AD mice develop both hallmark
Clearance of Intracellular and Extracellular A lesions of AD neuropathology and because anti-A
Antibodies against Awere administered by intrahippo- antibody treatment effectively clears extracellular and
campal injections into hemizygous and homozygous intracellular Adeposits, we assessed whether adminis-
3xTg-AD mice (Table 1). The 3xTg-AD mice develop both tration of an anti-tau antibody could reduce the tau bur-
plaques and tangles in an age-progressive and region- den in the CA1 pyramidal neurons of the hippocampus.
specific manner that closely mimics the hierarchical We found that the tau pathology was unaffected follow-
pattern observed in human AD (Oddo et al., 2003b). The ing intrahippocampal administration of the anti-tau mono-
neuropathology that develops in the hemizygous and clonal antibody HT7, which recognizes all isoforms of
homozygous 3xTg-AD mice is indistinguishable, al- human tau (Figures 2A, 2B, and 2I). Recall that the HT7
though the onset is slower in the hemizygous group antibody treatment had no effect on the A pathology
(Oddo et al., 2003a). Consequently, the outcome of the (Figures 2C, 2D, and 2I). Finally, the tau pathology was
immune-based treatments can be evaluated in mice with also unaffected by intrahippocampal administration of
different degrees of neuropathology, but where the ef- an anti-protozoan isotype control antibody or by PBS
fect of age and genetic background is not a confound- (Figure 3). Therefore, tau immunotherapy had no dis-
ing variable. cernible effect on the tau pathology.
In the first experiment, a single, intrahippocampal in- Notably, administration of the anti-Amonoclonal an-
jection of the anti-A monoclonal antibody 1560 or 4G8 tibodies 4G8 or 1560 effectively cleared the early tau
was administered to 12-month-old hemizygous 3xTg- pathology in the somatodendritic compartment of neu-
AD mice (Figure 1). 7 days postinjection, there was a rons within the injected hippocampi (Figures 2E–2H, 2J,
marked reduction in extracellular deposits as deter- and 2K). No clearance of tau was observed in the contra-
mined by A immunostaining in the ipsilateral hippo- lateral, uninjected hippocampi (Figures 2E and 2G). In
campus in mice receiving the A antibody (Figure 1A). the A-injected hippocampi, tau staining was absent in
Moreover, thioflavin-S-positive structures were also di- regions immediately surrounding and extending from
minished, further demonstrating clearance of extracellu-
the injection site, but the effect was not due to damage
lar plaques (cf. Figures 1B and 1C) and also establishing
to the CA1 neurons from the injection cannula as they
that the lack of A detection in the ipsilateral hippocam-
appeared morphologically unaltered by hematoxylinpus was not due to competition between the injected
and eosin staining (Figures 8A–8C). In some cases, aantibody and the secondary antibody used during the
near total lack of tau immunoreactivity occurred in theimmunostaining procedure. Not only were extracellular
injected hippocampi, though the contralateral hippo-A deposits reduced, but we also found that the anti-
campi retained extensive tau pathology. These resultsbody treatment led to a diminution in the number of
indicate that the clearance of the tau load from the so-A-immunoreactive neurons around the site of injection,
matodendritic compartment, indicative of early tau pa-indicating that intracellular Awas also cleared (Figures
thology, by the anti-A antibody is a selective process1D–1G). Clearance of both extracellular and intracellular
that neither depends on a generalized IgG response norA occurred to the same extent using monoclonal anti-
is a consequence of an intracerebral injection artifact.bodies 4G8 or 1560 (Figures 2J and 2K), indicating that
Moreover, both antibodies 4G8 and 1560 effectivelythe effect was not limited to a specific antibody. Finally,
cleared the tau pathology, indicating that these resultsit is important to note that A pathology remained unaf-
are not unique to a specific anti-A antibody. Thesefected in the contralateral hippocampi (Figures 1A, 1B,
findings further suggest that there is direct relationship1D, and 1F), and injections of anti-tau antibody (Figures
between A and tau pathology and demonstrate that2C, 2D, and 2I), isotype control antibody, or PBS (Figure
clearance of A can lead to a subsequent reduction in3) had no apparent effect on A pathology in either the
ipsilateral or contralateral hippocampi. the tau burden.
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rons, yet a rich pattern of human-specific tau immuno-
staining remained in both the ipsilateral and contralat-
eral hippocampi (cf. Figures 4A–4D with 4E–4H; Figure
5A). By 5 days postinjection, both the A and tau burden
were cleared (data not shown), paralleling the results
observed at 7 days postinjection (Figures 1 and 2). There-
fore, these results established that there is a hierarchical
pattern to the antibody-mediated clearance of the two
hallmark lesions, with A clearance initiating the removal
of tau pathology.
We next investigated the time course by which both
pathologies reemerged following the antibody treat-
ment. Accordingly, 3xTg-AD mice were sacrificed 30
and 45 days after a single anti-A antibody injection.
By 30 days, the A pathology had reemerged and the
level of staining was comparable between the ipsilateral
and contralateral hippocampi (cf. Figures 4K and 4L;
Figure 5B). Notably, the tau pathology had not yet re-
emerged at this time point in the ipsilateral hippocam-
pus, despite dense tau staining in the contralateral hip-
pocampus (cf. Figures 4O and 4P; Figure 5B). By day
45 after antibody treatment, the level of tau staining
between the ipsilateral and contralateral hippocampi is
comparable, indicating that the tau pathology re-
emerges between days 31 and 45 (cf. Figures 4W and
4X; Figure 5C).
These findings indicate that there is a hierarchical
pattern to the clearance and reemergence of the A and
tau neuropathology following antibody treatment. The
A load is reduced prior to the tau burden, and con-
versely, the A pathology reemerges well in advance of
the tau pathology. Further corroborating a hierarchical
relationship between A and tau is our previous finding
that, despite the equivalent expression levels of the APP
Figure 1. Intrahippocampal Administration of Anti-A Antibodies
and tau transgenes in this model, the A pathology pre-Clears Both Intracellular and Extracellular A Aggregates
cedes the development of the tau pathology (Oddo et al.,The anti-A monoclonal antibody, 1560, was administered via intra-
2003b). Taken together, these data provide compellinghippocampal injections into 12-month-old hemizygous 3xTg-AD
evidence for the amyloid cascade hypothesis, that Amice (n  11).
(A) Low-magnification view of the hippocampus/neocortex showing lies upstream of tau in the neurodegenerative cascade
the contralateral (uninjected) and ipsilateral (injected) sides. Arrows leading to AD, and further suggest that A-based thera-
on the right side denote the cannula track. Note the reduction in peutic approaches may be efficacious in removing both
the number of A immunoreactive deposits in the ipsilateral hippo-
hallmark lesions.campus surrounding the site of injection.
(B and C) Intrahippocampal anti-A injection reduced the number
of thioflavin S-positive structures. Clearance of Tau Is Dependent on Its
(D–G) Low- and high-magnification views of the hippocampus/CA1 Phosphorylation State
pyramidal cell layer showing that a single administration of A anti- Because hyperphosphorylation of tau is a critical step
body is sufficient to markedly reduce intracellular A immunoreac-
in the pathway leading to neurofibrillary pathology, wetivity.
determined whether the A-mediated clearance of tau
was dependent on its phosphorylation state. At 12
months of age, homozygous 3xTg-AD mice show exten-Temporal Pattern of A and Tau Clearance
The reduction of the tau pathology by utilization of an sive tau hyperphosphorylation in CA1 pyramidal neu-
rons and are immunopositive for tau antibodies MC1,anti-A antibody suggests a direct relationship between
the development and expression of these two neuro- AT8, and AT180 (Oddo et al., 2003b); MC1 recognizes
conformational changes in tau, an early requirement forpathological lesions. Indeed, if such a relationship ex-
ists, it may be possible to find a time point following tangle formation (Weaver et al., 2000), whereas the phos-
pho-specific tau antibodies, AT8 and AT180, recognizeadministration of the anti-A antibody when clearance
of A precedes the removal of the tau pathology. To tau phosphorylated at serine 202/threonine 205 and at
threonine 231, respectively. In contrast, comparabledetermine the time course of the antibody-mediated
clearance of the Aand tau pathology, we delivered anti- age-matched hemizygous mice are immunonegative for
AT8 and AT180 (Figure 6H; Oddo et al., 2003a). Conse-Aantibody 1560 into the hippocampus of 12-month-old
hemizygous 3xTg-AD mice and sacrificed them 3, 5, 7, quently, we assessed whether hyperphosphorylated tau
aggregates were diminished by the A-based immune30, or 45 days later (Figures 4 and 5). After only 3 days
postinjection, A was cleared from CA1 pyramidal neu- approach. Although the A deposits were effectively
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Figure 2. Clearance of Tau Aggregates in CA1 Pyramidal Neurons after Administration of Anti-A Antibodies
(A–D) Intrahippocampal injection of the human-specific anti-tau antibody, HT7, had no observable effect on either tau, as determined by HT7
immunostaining (cf. A and B), or A load, as determined by 1560 immunostaining (cf. C and D).
(E–H) Low- and high-magnification views of the hippocampus/CA1 pyramidal layer demonstrating that a single intrahippocampal administration
of the anti-A antibody, 1560, effectively reduced the tau burden in the ipsilateral hippocampus (F and H), compared to the contralateral
hippocampus (E and G). Arrows in (H) denote the CA1 pyramidal neuron layer.
(I–K) Quantitative assessment of the percentage change in the A and tau load after intrahippocampal injection of the tau antibody HT7 (I) or
the A antibodies 4G8 (J) or 1560 (K). Following administration of the anti-tau antibody (I), no significant difference was apparent between
the percentage of decrease of the ipsilateral:contralateral site within the injection site and the percentage decrease of the ipsilateral:contralateral
site 10 sections away from the injection site for both A and tau (p  0.4815 and p  0.3182). In contrast, following administration of either
anti-A antibody (J and K), the percentage of decrease of the ipsilateral:contralateral site within the injection site and the percentage decrease
of the ipsilateral:contralateral site 10 sections away from the injection site was significant for both A and tau (for both antibodies 1560 and
4G8, p  0.0001 for A and tau). Red and blue bars denote the A and tau load, respectively, in areas surrounding the injection site compared
to the same region in the contralateral site. Green and yellow bars denote the A and tau load, respectively, in comparable areas 10 sections
away from the injection site.
cleared by a single A antibody injection in the 12- transgene product are comparable between 6- and 12-
month-old homozygous mice (Figures 6J and 6K). Fol-month-old homozygous mice, only a small, but signifi-
cant, reduction in the tau load was observed, likely due lowing intrahippocampal administration of the anti-A
antibody in 6-month-old homozygous mice, both A andto the clearance of nonhyperphosphorylated tau (Fig-
ures 6A–6G). Note that the Gallyas silver method reveals tau pathology were cleared (Figure 7). In contrast, 12-
month-old homozygous mice show only a small de-that the tau load is comparable between the ipsi- and
contralateral sections, indicating that aggregated tau crease in the tau load (Figures 6C–6G). Therefore, we
conclude that the removal of pathological tau from thewas unaffected by the antibody treatment (Figures 6E
and 6F). somatodendritic compartment is critically dependent on
its phosphorylation state: hyperphosphorylated tau ag-Two factors could account for the differential clear-
ance of tau in the hemizygous versus homozygous mice: gregates appear to be resistant to A-mediated clear-
ance. By extension, our results suggest that A-based(1) hyperphosphorylation renders the tau aggregates re-
sistant to A-mediated removal, or (2) there is a higher immune approaches may effectively clear both A and
tau lesions provided that it is administered early duringtau load in the homozygous mice, which express twice
as much tau transgene compared to the hemizygous the disease course.
mice. To distinguish between these possibilities, we ad-
ministered A antibody into the hippocampus of 6-month- Mechanism of Immune-Mediated Clearance
of Tau Is Dependent on the Proteasomeold homozygous 3xTg-AD mice. At 6 months of age, the
homozygous mice do not show evidence of tau hyper- While novel, the finding that the tau pathology was
cleared by antibodies targeted against A raised thephosphorylation (similar to the 12-month-old hemizygous
3xTg-AD mice), yet steady-state levels of the human tau question as to the mechanism underlying this process.
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Figure 3. A and Tau Load Were Unaffected after Intrahippocampal Injection of an Isotype Control Antibody or PBS
(A–D) A (A and B) and tau (C and D) immunoreactive structures were labeled to the same extent in the contralateral and ipsilateral hippocampus
following administration of an anti-protozoan antibody (isotype-control).
(E–H) Intrahippocampal administration of PBS had no effect on the A (E and F) or tau (G and H) load. Arrows in (H) denote the cannula track.
(I and J) Quantitative assessment of the percentage change in the A and tau load after intrahippocampal injection of an isotype control
antibody (I) or PBS (J). Red and blue bars denote the A and tau load, respectively, in areas surrounding the injection site compared to the
same region in the contralateral site. Green and yellow bars denote the A and tau load, respectively, in comparable areas about 10 sections
away from the injection site. No significant changes were denoted between the percentage of decrease of the ipsilateral:contralateral site
within the injection site and the percentage decrease of the ipsilateral:contralateral site 10 sections away from the injection site for both A
and tau ([I], p  0.4407 and p  0.8901 for A and tau, respectively; [J], p  0.9692 and p  0.3503 for A and tau, respectively).
To address this issue, we first determined whether the of tau immunoreactivity between the contra- and ipsilat-
eral sides, despite a significant difference for A (FigureA antibody treatment affected the steady-state levels
of the APP holoprotein in the injected hippocampi. As 9I). Although we cannot exclude that tau may be re-
moved by other mechanisms, we conclude that A inter-shown in Figures 8D–8G, the levels of the APP holopro-
tein were comparable between the injected and unin- feres with proteasome activity and that its removal via an
antibody-mediated process alleviates this impairment,jected hippocampus, indicating that the A antibody
treatment lowered the A burden without affecting APP allowing for the clearance of the tau pathology.
transgene levels.
Several reports indicate that the activity of the protea- Inhibiting A Formation Also Leads to Clearance
of Tau Pathologysome can be adversely affected by A and hyperphos-
phorylated tau (Gregori et al., 1995, 1997; Keck et al., We demonstrated that A immunotherapy leads to the
clearance of pathological tau from the somatodendritic2003). Consequently, we investigated whether protea-
some activity was essential to the clearance of the tau compartment of neurons. The effect is specific for anti-A
antibodies as anti-tau and isotype control antibodiespathology in the 3xTg-AD mice by injecting the protea-
some inhibitor, epoxomicin (Lindsten et al., 2003), con- and vehicle-only injections failed to have any overt effect.
Nevertheless, we utilized an unrelated approach to de-comitantly with the A antibody, 1560. As expected, this
dual treatment had little effect on the clearance of the termine if reducing the A load also affected the patho-
logical tau burden. The -secretase inhibitor, DAPT, hasA pathology (Figures 9A–9D and 9I), as its clearance
is mediated by an immune-based reaction. However, previously been shown to lower A levels within 12 hr
following a single injection into transgenic mice (Doveyinhibiting proteasome activity adversely affected the
clearance of tau (Figures 9E–9I). Note that the level of et al., 2001; Lanz et al., 2003). We intrahippocampally
injected this compound and found that there was atau staining is comparable between the uninjected con-
tralateral side and the ipsilateral side. Quantitative as- marked reduction in the A and tau burden in the ipsilat-
eral side, compared to the contralateral hippocampisessment indicated there was no difference in the level
Neuron
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Figure 4. Clearance and Reemergence of A and Tau Pathologies Is Hierarchical
(A–H) A clearance occurs prior to the removal of the tau aggregates in 12-month-old hemizygous 3xTg-AD mice. 3 days after anti-A antibody
administration, A staining was reduced in the ipsilateral hippocampi (B and D), whereas the contralateral hippocampi were unaffected (A
and C). The tau burden was not cleared at 3 days postinjection as the contralateral and ipsilateral sides were stained to comparable levels
(cf. G and H). The tau burden, however, was markedly reduced in anti-A injected hippocampi at 5 and 7 days postinjection (data not shown
and Figures 2F and 2H).
(I–X) A pathology reemerges prior to tau pathology. 30 days after a single anti-A antibody injection, reemergence of A immunostaining is
apparent in the ipsilateral hippocampus (cf. K and L), whereas tau immunostaining is still not apparent in areas surrounding the injection site
(cf. O and P). At 45 days after a single anti-A antibody injection, the level of A (Q–T) and tau (U–X) immunostaining are comparable between
the ipsilateral and contralateral sides.
(Figure 10). These results show that blocking the forma- markedly reduces extracellular as well as intracellular
tion of A leads to the clearance of early tau pathology. A. To our knowledge, this is the first report to document
These data provide strong corroborating evidence of the clearance of intracellular A pools following A-based
immunotherapeutic results presented earlier and further immunotherapy. Although it remains to be established
support a direct relationship between A and tau pa- if intracellular A is the precursor to the extracellular
thology. deposits (see review article by Tseng et al., 2004), the
antibody-mediated clearance of intracellular A from
Discussion pyramidal neurons suggests that there is a dynamic
relationship between the intracellular and extracellular
pools. It is important to note that the reduction in intra-In this study, we demonstrate that a single intrahippo-
campal injection of an anti-A antibody rapidly and cellular A was not caused by a decrease in the levels
A Therapy Leads to Clearance of Tau Pathology
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mislocalization of tau from the axon to the somatoden-
dritic compartment represents a critical and presumably
early event in the development of tauopathies. It is
notable that tau immunotherapy was ineffective at re-
ducing the tau burden, whereas effective clearance
occurred following administration of anti-A antibodies or
a-secretase inhibitor. These data provide strong evidence
supporting a direct link between A and tau pathology in
AD. The mechanism underlying the A-mediated clear-
ance of tau is dependent on proteasome function, as
inhibiting its activity prevents tau clearance.
Proteasome Dysfunction in Alzheimer’s Disease
The proteasome is a multiunit catalytic complex that is
responsible for degrading misfolded or damaged pro-
teins (Goldberg, 2003). Dysfunction of the proteasome
system in the CNS may lead to the intraneuronal accu-
mulation of potentially toxic aggregates, which subse-
quently may cause neuron degeneration and death. Sev-
eral studies have reported a decrease in proteasome
activity in the AD brain (Keller et al., 2000; Lopez Salon
et al., 2000). The reason for diminished proteasome ac-
tivity is unclear, although several authors have sug-
gested that A or tau-paired helical filaments may un-
derlie this effect (Gregori et al., 1995, 1997; Keck et al.,
2003). Based on the hierarchical pattern of clearance
reported here, we suggest that intraneuronal accumula-
tion of A impairs proteasome function and allows the
accumulation of potentially toxic aggregates such as
aggregation-prone tau protein. Clearance of A (includ-Figure 5. Quantitative Assessment of A and Tau Pathology at 3,
30, and 45 Days after Antibody Administration ing the intracellular species) presumably alleviates this
(A) At 3 days after antibody injection, there is a significant decrease impairment, allowing tau to be cleared by the protea-
in the A load (p  0.0006), whereas tau load was not significantly some. Furthermore, the results presented here show
different (p  0.7149). that the A-mediated clearance of tau is critically depen-
(B) At 30 days after antibody administration, the difference between
dent on its phosphorylation state, with hyperphosphory-percentage of decrease of the ipsilateral:contralateral site within
lated tau aggregates resistant to clearance. This findingthe injection site and the percentage decrease of the ipsilateral:con-
agrees well with other in vitro studies demonstratingtralateral site 10 sections away from the injection was still significant
for A (p 0.0135) but greatly attenuated compared to the difference that nonhyperphosphorylated tau can be degraded by
observed 3 days (A) and 7 days after antibody administration, indi- the proteasome system (David et al., 2002; Goldbaum
cating that A pathology is reemerging. et al., 2003).
(C) At 45 days after antibody administration, neither the A or tau
burden appeared significantly different between the ipsi- and con-
A and Tau Interactions In Vivotralateral sides (p  0.1332 and 0.6572, respectively).
Red and blue bars denote the A and tau load, respectively, in areas These two hallmark lesions are cleared in a hierarchical
surrounding the injection site compared to the same region in the fashion, with the clearance of A preceding the abroga-
contralateral site. Green and yellow bars denote the A and tau tion of the tau burden. Likewise, the A deposits re-
load, respectively, in comparable areas about 10 sections away emerge in advance of the tau pathology. Taken together,
from the injection site.
these results strongly suggest a link between A and
tau. These findings also provide strong supporting evi-
dence for the amyloid cascade hypothesis, which stipu-of the APP holoprotein. Overall, the finding that intracel-
lular Amay be cleared may have important therapeutic lates that A accumulation triggers the onset of AD and
that tau hyperphosphorylation, subsequent neurofibril-implications for the degenerating muscle disorder inclu-
sion body myositis, which is characterized by the occur- lary tangle formation, and cell death are downstream
consequences of A aggregation (Hardy and Selkoe,rence of intracellular (but not extracellular) Aaccumula-
tion in affected myofibers (Mendell et al., 1991). The 2002). Mounting evidence, including reports from other
in vivo studies, suggests that the A and tau pathologiesfindings presented here demonstrate that an A-based
immunotherapeutic approach may clear intracellular A are linked. Lewis et al. (2001) reported enhanced tau
pathology after crossing a transgenic line overexpress-in muscle cells as effectively as was shown for neurons.
The clearance of early tau pathology from the somato- ing mutant APP with another, independent line overex-
pressing mutant tau. Likewise, Gotz et al. (2001) showeddendritic compartment of CA1 pyramidal neurons of the
3xTg-AD brain, following A immunotherapy or -secre- that injection of fibrillar A into the brains of transgenic
mice overexpressing tauP301L markedly increased thetase inhibitor treatment, is the most significant finding
to emerge from these studies, and to our knowledge number of neurofibrillary tangles in the amygdala. Our
laboratory has also shown that overexpression of humanrepresents the first report of their clearance from the
mammalian brain. This finding is significant because the APP in transgenic mice can modulate the neurofibrillary
Neuron
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Figure 6. Hyperphosphorylated Tau Aggregates Are Resistant to A-Mediated Clearance
(A and B) Both intracellular and extracellular A deposits are cleared from the hippocampal regions of 12-month-old homozygous 3xTg-AD
mice following administration of an anti-A antibody (n  5).
(C–F) Administration of an anti-A antibody did not appear to clear tau aggregates from the 12-month-old homozygous 3xTg-AD mice as
determined by HT7 immunostaining (C and D) and Gallyas silver staining (E and F).
(G) Quantitative assessment of the percentage change in the A and tau load after intrahippocampal injection of the A antibody 1560 into
the brains of 12-month-old homozygous 3xTg-AD mice. The percentage of decrease of A between the ipsilateral: contralateral site within
the injection site and the percentage decrease of the ipsilateral:contralateral site 10 sections away from the injection site was statistically
significant. Despite the prominent immunostaining of tau in the ipsilateral side (D), there was also a small but statistically significant reduction,
presumably due to clearance of nonhyperphosphorylated tau. *p  0.0001; **p  0.0011. Red and blue bars denote the percentage change
in A and tau load, respectively, in areas surrounding the injection site compared to the same region in the contralateral site. Green and
yellow bars denote the A and tau load, respectively, in comparable areas about 10 sections away from the injection site.
(H and I) The disparity in tau clearance between the hemizygous and homozygous mice is likely due to the disparity in the hyperphosphorylation
state of tau; AT8-positive tau staining is readily apparent in 12-month-old homozygous mice (I) but devoid in age-matched hemizygous mice
(H) and in 6-month-old homozygous mice (not shown).
(J) Representative Western blot of tau steady-state levels in 6- and 12-month-old homozygous mice.
(K) Quantitative analysis reveals no significant differences in tau steady-state levels in 6- and 12-month-old homozygous mice.
pathology, as double transgenic mice (PS1M146V/M146V insufficient to impact the neurofibrillary pathology. It is
critical to note, however, that only one tau antibody wasKI/tauP301L) develop tau pathology much later than the
3xTg-AD mice, despite equivalent expression of the tau tested during these studies. Therefore, it is essential
that other tau antibodies, including those that recognizetransgene in both models (Oddo et al., 2003b). Finally,
other groups have also shown that tau is essential for hyperphosphorylated and conformation-specific epitopes,
be evaluated for their efficacy in removing tau from theA-induced neurotoxicity (Rapoport et al., 2002; Riss-
man et al., 2004). mammalian brain. These findings raise the intriguing
possibility that a multiantibody-based approach (i.e.,
one targeted against A and one against tau) may pro-Concluding Remarks
There are several therapeutic implications of this study. vide the most significant clinical benefit for the treatment
of AD. Finally, we conclude that the A-mediated clear-The most clinically relevant finding is that using anti-
A-based therapeutic approaches can clear the tau bur- ance of tau from the 3xTg-AD brains suggests that tau
aggregates are also in a dynamic state and that immune-den. Because the clearance of the tau pathology is de-
pendent on its phosphorylation state, it indicates that or pharmacologic-based strategies may also be effec-
tive for treating tauopathies, such as corticobasal de-A immunotherapy late during the disease course may
still effectively clear amyloid plaques, although it will be generation, frontotemporal dementia with Parkinsonism
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Figure 8. Clearance of A/Tau Is Not Due to Neuronal Damage, nor
to Changes in APP Steady-State Levels
(A–C) Hematoxylin-eosin staining shows that the CA1 pyramidal
neurons appear morphologically unaltered in both the ipsilateral and
contralateral hemispheres, indicating that clearance was specific
for the anti-A antibody treatment and not due to unintentionalFigure 7. Clearance of the Tau Burden from Young Homozygous
damage by the injection procedure. (B) and (C) show high-magnifica-3xTg-AD Mice by A Immunotherapy
tion views of the contra- and ipsilateral subiculum/CA1 region, re-(A–D) Administration of the anti-A antibody leads to a marked
spectively.reduction in the tau burden in the hippocampus of 6-month-old
(D–G) Steady-state levels of APP were comparable between thehomozygous 3xTg-AD mice. At this age, tau is not extensively hyper-
ipsi- and contralateral hippocampi after a single injection of an anti-phosphorylated. These studies show that the increased steady-
A antibody, indicating that the clearance of A is not likely due tostate levels of tau in the homozygous (versus hemizygous) mice do
diminished formation from APP. (F) and (G) show higher-magnifica-not represent a hindrance to clearance by A-based immunother-
tion views of (D) and (E).apy. These findings support the hypothesis that the phosphorylation
state of tau is a critical determinant in its ability to be cleared by
or PBS vehicle were injected into the left hippocampus through aanti-A antibodies.
33-gauge injector attached to a 5 l Hamilton syringe (Hamilton(E) Quantitative assessment of the percentage change in the A and
Company, Reno, NV). The coordinates, with respect to bregma,tau load after intrahippocampal injection of the A antibody 1560
were 2.7 mm posterior, 2.5 mm lateral, and 3.0 ventral to theinto the brains of 6-month-old homozygous 3xTg-AD mice. For both
skull. Injections occurred over the span of 5 min, after which theA and tau, the percentage of decrease in the ipsilateral:contralat-
cannula was left in place for an additional 5 min to allow for diffusion.eral site within the injection site differed significantly from the per-
Animals were kept on a warming pad until they had fully recoveredcentage decrease of the ipsilateral:contralateral site 10 sections
from anesthesia and were kept in individual cages until they wereaway from the injection site (A: p  0.001; tau: p  0.0007). Red
sacrificed for tissue processing to prevent damage to the scalpand blue bars denote the A and tau load, respectively, in areas
sutures. All animal procedures were in accordance with the Nationalsurrounding the injection site compared to the same region on the
Institutes of Health Guide for the Care and Use of Laboratory Animalscontralateral side. Green and yellow bars denote the A and tau
and all appropriate measures were taken to minimize pain and dis-load, respectively, in comparable areas about 10 sections from the
comfort in experimental animals.injection site.
Antibodies and Inhibitors
The following antibodies were injected during the surgeries: anti-
linked to chromosome 17, and progressive supranu- A antibodies 1560 (1 g/l) (Chemicon) or 4G8 (1 g/l) and anti-
clear palsy. tau HT7 (1 g/l) (Innogenetics). The following antibodies were used
for immunohistochemistry and Western blotting: anti-A 6E10 and
Experimental Procedures 4G8 (Signet Laboratories, Dedham, MA), anti-A 1560, anti-Tau HT7,
AT8 (Innogenetics), Tau 5 (Calbiochem), and anti-actin (Sigma). Pri-
Mice and Surgical Procedures mary antibodies were applied at dilutions of 1:1000 for 6E10, 1:3000
The 3xTg-AD mice used in this study have already been character- for 1560, 1:500 for AT8 and AT180, 1:1000 for HT7, and 1:200 for
ized (Oddo et al., 2003a, 2003b). Male and female 3xTg-AD mice 22C11. The proteasome inhibitor epoxomicin (Sigma) was intrahip-
weighing 25–49 g at the time of surgery were group housed and pocampally injected (15 g) in combination with anti-A antibody
kept on a 12 hr light:12 hr dark schedule. All mice were given ad 1560. The -secretase inhibitor, DAPT (Calbiochem), was also in-
libitum access to food and water. Surgeries were carried out during jected into the hippocampus.
the light cycle. Homozygous and hemizygous mice were anesthe-
tized with avertin (1.3% tribromoethanol, 0.8% amylalcohol, given Immunohistochemistry
0.6 ml/25 g body weight) and placed in a stereotactic apparatus Mice were sacrificed by CO2 asphyxiation and the brains were fixed
for 48 hr in 4% paraformaldehyde. 50 m thick free-floating sections(MyNeuroLab, St. Louis, MO) with a mouse adaptor. Antibodies (2l)
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Figure 9. Clearance of Tau Is Dependent on Proteasome Activity
(A–D) Immunotherapy-mediated clearance of A is not dependent on the proteasome. The proteasome inhibitor, epoxomicin, and the mono-
clonal antibody 1560 were concomitantly injected into the hippocampus of 12-month-old hemizygous mice. Even in the presence of the
proteasome inhibitor, A levels were significantly reduced.
(E–H) Inhibiting the proteasome prevents A-mediated clearance of tau. Unlike the case for A, there was no significant clearance of tau in
the presence of the proteasome inhibitor.
(I) Quantitative assessment of the percentage change in the A and tau load following concomitant intrahippocampal injection of the A
antibody 1560 and the proteasome inhibitor epoxomicin, into the brains of 12-month-old hemizygous 3xTg-AD mice. For A, the percentage
of decrease in the ipsilateral:contralateral site within the injection site differed significantly from the percentage decrease of the ipsilateral:contra-
lateral site 10 sections away from the injection site (p  0.0001). For tau, however, no significant reduction was apparent (p  0.1351). These
findings indicate that clearance of tau pathology is dependent on the proteasome, whereas A clearance is not. Red and blue bars denote
the A and tau load, respectively, in areas surrounding the injection site compared to the same region on the contralateral side. Green and
yellow bars denote the A and tau load, respectively, in comparable areas about 10 sections away from the injection site.
Figure 10. Inhibiting A Formation also
Leads to the Clearance of Tau Pathology
The -secretase inhibitor, DAPT, was admin-
istered via intrahippocampal injection into 12-
month-old hemizygous 3xTg-AD mice (n 
3). Representative microphotographs of the
hippocampus/CA1 pyramidal cell layer show
that a single administration of DAPT is suffi-
cient to markedly reduce both A and tau pa-
thology.
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